STATIN-FIBRATE REPORT: Focus on Safety

In a letter to the editor, pharmacists working with the FDA collected all cases of statin-associated fatal rhabdomyolysis that had been reported to the FDA before June 26, 2001.77 Cases were included if there was a clinical diagnosis of rhabdomyolysis, a temporal association between rhabdomyolysis and the use of a statin, and death was either ... ................
................